[go: up one dir, main page]

EP2010213A4 - Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile - Google Patents

Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Info

Publication number
EP2010213A4
EP2010213A4 EP07755184A EP07755184A EP2010213A4 EP 2010213 A4 EP2010213 A4 EP 2010213A4 EP 07755184 A EP07755184 A EP 07755184A EP 07755184 A EP07755184 A EP 07755184A EP 2010213 A4 EP2010213 A4 EP 2010213A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
rheumatoid arthritis
juvenile rheumatoid
juvenile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07755184A
Other languages
German (de)
English (en)
Other versions
EP2010213A2 (fr
Inventor
Edward H Giannini
John R Medich
Alberto Martini
Daniel J Lovell
Nicolino Ruperto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Priority to EP13172516.0A priority Critical patent/EP2666479A3/fr
Publication of EP2010213A2 publication Critical patent/EP2010213A2/fr
Publication of EP2010213A4 publication Critical patent/EP2010213A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07755184A 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile Withdrawn EP2010213A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13172516.0A EP2666479A3 (fr) 2006-04-10 2007-04-10 Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79090906P 2006-04-10 2006-04-10
US80977006P 2006-05-30 2006-05-30
US81548906P 2006-06-20 2006-06-20
US85837606P 2006-11-10 2006-11-10
PCT/US2007/008826 WO2007120651A2 (fr) 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13172516.0A Division EP2666479A3 (fr) 2006-04-10 2007-04-10 Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Publications (2)

Publication Number Publication Date
EP2010213A2 EP2010213A2 (fr) 2009-01-07
EP2010213A4 true EP2010213A4 (fr) 2010-08-11

Family

ID=38610129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07755184A Withdrawn EP2010213A4 (fr) 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Country Status (2)

Country Link
EP (1) EP2010213A4 (fr)
WO (1) WO2007120651A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012502A2 (fr) * 2000-08-07 2002-02-14 Centocor, Inc. Anticorps anti-tnf, compositions, methodes et utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
CA2385745C (fr) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012502A2 (fr) * 2000-08-07 2002-02-14 Centocor, Inc. Anticorps anti-tnf, compositions, methodes et utilisations

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BREEDVELD F C ET AL: "The efficacy and safety of Adalimunab (Humira((R))) plus Methotrexate vs. Adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis (RA): 1-and 2-year results of the premier study", July 2005, ANNALS OF THE RHEUMATIC DISEASES, VOL. 64, NR. SUPPL. 3, PAGE(S) 60, ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, ISSN: 0003-4967, XP009132992 *
CHIKANZA IAN C: "Juvenile rheumatoid arthritis: therapeutic perspectives.", PAEDIATRIC DRUGS 2002 LNKD- PUBMED:11994038, vol. 4, no. 5, 2002, pages 335 - 348, XP009132928, ISSN: 1174-5878 *
HASHKES PHILIP J ET AL: "Medical treatment of juvenile idiopathic arthritis.", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 5 OCT 2005 LNKD- PUBMED:16204667, vol. 294, no. 13, 5 October 2005 (2005-10-05), pages 1671 - 1684, XP002580537, ISSN: 1538-3598 *
HORNEFF G: "Treatment of juvenile idiopathic arthritis", ZEITSCHRIFT FÜR RHEUMATOLOGIE, STEINKOPFF-VERLAG, DA LNKD- DOI:10.1007/S00393-005-0748-Y, vol. 64, no. 5, 1 June 2005 (2005-06-01), pages 317 - 326, XP019382946, ISSN: 1435-1250 *
LAHDENNE P ET AL: "Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study.", ANNALS OF THE RHEUMATIC DISEASES, vol. 62, no. 3, March 2003 (2003-03-01), pages 245 - 247, XP009132942, ISSN: 0003-4967 *
LOVELL D: "Biologic agents for the treatment of juvenile rheumatoid arthritis: Current status", PEDIATRIC DRUGS 2004 NZ LNKD- DOI:10.2165/00148581-200406030-00001, vol. 6, no. 3, 2004, pages 137 - 146, XP009132929, ISSN: 1174-5878 *
LOVELL DANIEL J ET AL: "Etanercept in children with polyarticular juvenile rheumatoid arthritis", NEW ENGLAND JOURNAL OF MEDICINE, vol. 342, no. 11, 16 March 2000 (2000-03-16), pages 763 - 769, XP002580532, ISSN: 0028-4793 *
LOVELL DANIEL J ET AL: "Preliminary data from the study of adalimumab in children with Juvenile Idiopathic Arthritis", ARTHRITIS & RHEUMATISM, vol. 50, no. Suppl. S, 1096, 2004, & 68TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY; SAN ANTONIO, TX, USA; OCTOBER 16 -21, 2004, pages S436 - S437, XP009132938, ISSN: 0004-3591 *
MARTINI GIORGIA ET AL: "Juvenile idiopathic arthritis: current and future treatment options.", EXPERT OPINION ON PHARMACOTHERAPY MAR 2006 LNKD- PUBMED:16503811, vol. 7, no. 4, March 2006 (2006-03-01), pages 387 - 399, XP009132927, ISSN: 1744-7666 *
WEISS J E ET AL: "Juvenile idiopathic arthritis", PEDIATRIC CLINICS OF NORTH AMERICA 200504 US LNKD- DOI:10.1016/J.PCL.2005.01.007, vol. 52, no. 2, April 2005 (2005-04-01), pages 413 - 442, XP009132933, ISSN: 0031-3955 *

Also Published As

Publication number Publication date
WO2007120651A3 (fr) 2008-07-31
EP2010213A2 (fr) 2009-01-07
WO2007120651A2 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
EP2010214A4 (fr) Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
EP2010213A4 (fr) Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile
EP2007426A4 (fr) Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL190520A0 (en) Compositions and methods for treatment of autoimmune
EP2104513A4 (fr) Compositions d'anticorps ovr110 et leurs procédés d'utilisation
EP2004666A4 (fr) Mutation de ras et compositions et méthodes associées
IL200766A0 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
IL197945A (en) Liquid Zalcogenic Preparations and Methods for their Preparation
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
PL1816116T6 (pl) Kompozycje chemiczne i sposoby ich wytwarzania
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
PL2069467T3 (pl) Kompozycje wydzielające i sposoby stosowania
PL2631241T3 (pl) Sposób generowania białka i jego zastosowanie
IL197528A0 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
EP1996218A4 (fr) Méthodes et compositions servant au traitement de troubles gastro-intestinaux
EP2104554A4 (fr) Compositions de particules
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
IL211704A0 (en) Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
EP2109673A4 (fr) Procedes et compositions pour l'expression et la purification de proteines ameliorees
EP2049151A4 (fr) Méthodes et compositions pour le traitement du cancer
IL196411A0 (en) Anti-cocaine compositions and treatment
EP2124968A4 (fr) Compositions et procédés pour le traitement de l'atrophie musculaire
EP1912630A4 (fr) Compositions et procedes destines a reduire les douleurs postoperatoires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126676

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20100713

17Q First examination report despatched

Effective date: 20110609

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20081110

Extension state: HR

Payment date: 20081110

Extension state: MK

Payment date: 20081110

Extension state: BA

Payment date: 20081110

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE BIOTECHNOLOGY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126676

Country of ref document: HK